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RICHARD GOLDBERG, MEDICINAL PRODUCT LIABILITY AND 
REGULATION (HART PUBLISHING, OXFORD, 2013) 214PP 
In December 2013, settlement was reached between approximately 100 Australian 
and New Zealand Thalidomide victims and the company which had acted as the 
Australian distributor of the infamous drug, thus putting to rest the possibility of 
litigation.
1
 Around the same time, Thalidomide victims in the United Kingdom (UK) 
launched a similar bid for compensation against the manufacturer and distributor.
2
 It 
is clear that despite a lengthy amount of time having passed ever since the 
thalidomide disaster commenced in 1962, the controversy over compensation 
continues. Indeed, the author of Medicinal Product Liability and Regulation 
(published before the announcement of the British legal claim), Professor Goldberg, 
notes that claims for resulting birth defects continue to emerge right into the present 
day. His prescient insight into the contemporary relevance of compensation for 
pharmaceutical injuries thus makes Medicinal Product Liability and Regulation a 
very relevant addition to the small body of scholarship that is available on this rather 
specific and complex issue.  
Early on in the book, Goldberg seeks to examine the existing product liability 
regimes from a comparative law analysis, contrasting the strict liability regime found 
in the UK’s Consumer Protection Act 1987 against the compensation schemes found 
in Germany and Nordic states. He also makes the point that unlike the United States 
(US), the UK regime does not seek to distinguish pharmaceutical products from other 
general goods, but the nature of pharmaceutical products merit such a distinction, and 
it is on this foundation that much of the book appears to be based upon.  
Another key theme throughout the text appears to Goldberg’s championing of the US 
jurisprudence in this area, and a subtle plea for UK lawmakers to recognise the 
invaluable contribution that US law could make towards future reform. Due to the 
differences between the legal frameworks as well as culture of the US and the UK, 
the approach of the former cannot be directly adopted by the UK. Goldberg tackles 
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 this hurdle by continuing the comparative discussion throughout the chapters, 
highlighting the strengths of the US approach and using that to demonstrate the 
deficiencies in the UK law, thus ingeniously merging the two jurisdictions. The 
discussion takes the form of eight chapters: two introductory and the remaining six 
each focus on a specific topic in relation to medicinal product liability claims and 
regulation. A notable example of Goldberg’s holistic and balanced approach is the 
first issue-specific chapter of the text, being chapter three. It aptly focuses on the 
issue of design, which is one of three types of defect associated with pharmaceuticals 
and is arguably also the most controversial type. On discussing the test for 
determining whether a design is “defective”, Goldberg undertakes a detailed 
comparison between a test based on risk/utility (an approach favoured by current 
lawmakers in the US) and the UK consumer expectations test, to form a strong 
argument that risk/utility considerations are inevitable when it comes to 
pharmaceuticals.  
With Goldberg’s expertise on causation, as well as causation being one of the most 
difficult and controversial concepts in tort law generally, it is natural that the next 
issue addressed by Goldberg is causation. Chapter five is an extension of Goldberg’s 
previous work on this topic and considers the difficulties of using epidemiological 
evidence in determining legal causation, again with a focus on the laws of the UK and 
US, as well as Australia and Canada. Chapter six then provides a different sort of 
comparative perspective on the issue of causation by discussing in detail the closest 
example to drugs: vaccines. In this chapter, Goldberg traces the history of the 
Measles, Mumps and Rubella (MMR) vaccine litigation in Europe and the United 
States, which had been triggered by the 1998 Wakefield hypothesis about the 
association between the vaccine and autism. Goldberg ends by noting that Andrew 
Wakefield’s claims, which were published in The Lancet, were eventually discredited 
on the basis of fraud. 
Far from neglecting the “regulation” component of his book, and demonstrating the 
interconnectedness of regulation and liability, Goldberg delves into the defences to 
product liability by starting with whether regulatory compliance can and should act as 
a defence to product liability claims. Generally, he notes the administrative and 
evidentiary burdens associated with proving, or disproving regulatory compliance as 
a defence. Chapter eight is the final issue-specific chapter in the book and examines 
the development risk defence, which is just as controversial as the topic of 
pharmaceutical product liability generally and is indeed worthy of its own chapter.  
The development risk defence appears in the European Product Liability Directive,
3
 
article 7(e) and is emulated in the UK and Australian laws which have domestically 
implemented the Directive. Article 7(e) provides that ‘a producer shall not be liable if 
he proves … that the state of scientific and technical knowledge at the time when he 
                                                 
3
  Council Directive 85/374/EEC of 25 July 1985 on the Approximation of the Laws, Regulations and 
Administrative Provisions of the Member States concerning Liability for Defective Products [1985] 
OJ L 210/29. 
 put the product into circulation was not such as to enable the existence of the defence 
to be discovered’. Although the defence has been written about extremely 
comprehensively (possibly exhaustively), Goldberg’s synthesis of the history, the 
notable European Commission vs United Kingdom
4
 case which considered its 
interpretation, and the existing literature only serves to highlight the continuing 
controversy as to both the defence per se, and its hindrance to the otherwise strict 
liability nature of the European Directive.  
Throughout this review, Australian readers may be wondering how a book which 
focuses mainly on European and American medicinal product liability and regulation 
be of relevance to Australian law. The reasons are threefold. The first is for law 
reform purposes; just as Goldberg wrote this book with the aim of demonstrating the 
value of US jurisprudence for UK and European audiences, so too might Australian 
lawmakers and judges may see and appreciate the value of US jurisprudence in this 
area of law. During Australian law reform efforts in the past, US law had been 
overlooked in favour of European developments. Had the thalidomide claims not 
settled, and given the dearth of Australian case law on pharmaceutical product 
liability, one would hope that Australian courts would refer to the law of comparative 
jurisdictions for insight and guidance. Secondly, on a related note, although the 
number of pharmaceutical product liability claims in Australia is far lower than those 
seen in the history of the US, there has been a noticeable increase in Australian 
pharmaceutical and medical device litigation, with Vioxx and a range of allegedly 
faulty medical devices making frequent appearances in the national media. This 
context necessitates an examination of how the four year old Australian Consumer 
Law, enacted in 2010, does or should operate with respect to such products. Finally, 
one must remember that it is the Part 3-5 safety defect provisions of the Australian 
Consumer Law (and its Trade Practices Act 1974 (Cth) predecessor, Part VA) which 
implement the European Product Liability Directive into the domestic legal 
framework, much like the UK Consumer Protection Act 1987. Any work that 
discusses the interpretation and operation of the Directive and the UK legislation will 
be of direct relevance and interest to Australian law. 
When Part VA of the Trade Practices Act 1974 (Cth) was enacted in 1992, the 
Australian Attorney-General cautioned that any finding of a pharmaceutical or a 
vaccine as potentially defective due to associated adverse reactions had to be 
counterbalanced against potential benefits that such products conferred upon the 
wider community. Even back then, they were acutely aware of the uniqueness of 
pharmaceutical products compared to other consumer goods. Yet, like the UK, they 
refused to afford such products a tailored liability regime to reflect this uniqueness. 
Goldberg’s book, Medicinal Product Liability and Regulation provides insight into 
how a distinct regime for pharmaceutical products could operate. As one of the few 
monographs on the topic of medicinal and pharmaceutical product liability, it is a 
valuable addition to the scholarly literature in this field. Given Goldberg’s analysis of 
a wide range of topics in this controversial area, which spans across three 
                                                 
4
  Case C300/95 [1997] 3 CMLR 923.  
 jurisdictions, it is anticipated that this publication will be extremely useful for 
practitioners, academics, law students and those with a general interest in the area of 
product liability, pharmaceutical law or consumer protection generally. 
